Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64

View original at finance.yahoo.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 McCormick & Company, Incorporated (NYSE:MKC) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY26 adjusted EPS guidance of $3.05-$3.13 versus $3.09 consensus

    60% confidence
  • The company delivered growth in sales, operating income, and earnings per share, supported by the McCormick de Mexico acquisition and organic growth across both segments, alongside cost discipline that drove margin expansion

    60% confidence
  • Expected revenue growth of 13%-17% for FY26

    60% confidence
  • Certain AI stocks offer greater upside potential and carry less downside risk than MKC

    60% confidence
  • Projected tax rate of 24% for FY26

    60% confidence
  • McCormick price target lowered to $64 from $67 with Overweight rating maintained

    60% confidence
  • McCormick is not receiving the 'benefit of the doubt' from investors regarding its food deal

    60% confidence
  • Volumes were in line with expectations and anticipates sequential improvement through the year, supported by brand investments, innovation, and distribution gains

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
JPMorgan Lowers its Price Target on McCormick & Company. (MKC) to $64 — Source | Via News | Via News